Disease · MONDO_0003085

keratitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. keratitis. Diseases, record MONDO_0003085. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003085

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: keratitis; Open Targets
Open Targets ID: MONDO_0003085; Open Targets
Other names: Corneal inflammation, cornea inflammation, corneaitis, inflammation of cornea; Open Targets
Disease Ontology: DOID:4677; Disease Ontology
MeSH: D007634; MeSH
NCI Thesaurus: C26805; NCI Thesaurus
Highest stage of its drugs: Approval, for 11 of its 18 drugs, from DailyMed, EMA Human Drugs, FDA and PMDA; Open Targets

Drugs18

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CYCLOSPORINE	CHEMBL160	Protein	Approval	EMA Human Drugs	5	4	4	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	3	1	1	Drugs and targets
DEXAMETHASONE SODIUM PHOSPHATE	CHEMBL2021430	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
CENEGERMIN	CHEMBL4297852	Protein	Approval	EMA Human Drugs and FDA	2	0	0	Drugs and targets
GATIFLOXACIN	CHEMBL31	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
GENTAMICIN SULFATE	CHEMBL6067484	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
LEVOFLOXACIN	CHEMBL5315124	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
MOXIFLOXACIN HYDROCHLORIDE	CHEMBL1200735	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
OFLOXACIN	CHEMBL4	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets

1 to 10 of 18

See all 18 drugs

Targets9

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	4	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
NTRK1	Neurotrophic tyrosine kinase receptor	1	Neurotrophic tyrosine kinase receptor agonist	Approval	https://conductscience.org/library/genes/4914	Drugs and targets
NTRK2	Neurotrophic tyrosine kinase receptor	1	Neurotrophic tyrosine kinase receptor agonist	Approval	https://conductscience.org/library/genes/4915	Drugs and targets
NTRK3	Neurotrophic tyrosine kinase receptor	1	Neurotrophic tyrosine kinase receptor agonist	Approval	https://conductscience.org/library/genes/4916	Drugs and targets
P2RY1	P2Y purinoceptor 1	1	Purinergic receptor P2Y1 agonist	Phase 3	https://conductscience.org/library/genes/5028	Drugs and targets
P2RY2	P2Y purinoceptor 2	1	Purinergic receptor P2Y2 agonist	Phase 3	https://conductscience.org/library/genes/5029	Drugs and targets
P2RY4	P2Y purinoceptor 4	1	Pyrimidinergic receptor P2Y4 agonist	Phase 3	https://conductscience.org/library/genes/5030	Drugs and targets
P2RY6	P2Y purinoceptor 6	1	Pyrimidinergic receptor P2Y6 agonist	Phase 3	https://conductscience.org/library/genes/5031	Drugs and targets
PPIA	Peptidyl-prolyl cis-trans isomerase A	1	Cyclophilin A modulator	Approval	https://conductscience.org/library/genes/5478	Drugs and targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01751126	Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis	Phase 3	169	2022-03-28	Vernal Keratoconjunctivitis	CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov
NCT03237936	Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis	Phase 4	17	2024-04-18	Keratitis	CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov
NCT00081835	Evaluation and Treatment of Eye Complications of Vaccinia Vaccination	Phase 2	400		Vaccinia	VACCINIA IMMUNE GLOBULIN	Its record names the disease	ClinicalTrials.gov
NCT00732446	Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis	Phase 3	100		Blepharitis, Conjunctivitis, Keratitis	DEXAMETHASONE, MOXIFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT06903884	3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis	Phase 3	94		Vernal Keratoconjunctivitis	CYCLOSPORINE, DIQUAFOSOL	Its record names the disease	ClinicalTrials.gov
NCT04492878	Efficacy and Safety of Ikervis Under Controlled Environmental Conditions Environment	Phase 4	25		Dry Eye, Dry Eye Syndromes, Severe Keratitis	CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov
NCT01721694	Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection	Phase 3	0		Ocular Inflammation, Infection Associated Blepharitis, Keratitis, Conjunctivitis, Bacterial	AZITHROMYCIN, LOTEPREDNOL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
38446281	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003085

GET https://conductscience.org/api/diseases/v1/MONDO_0003085/drugs

API reference For AI assistants